Amphastar Pharmaceuticals, Inc.
AMPHHealthcare|Drug Manufacturers - Specialty & Generic|US
$28.49
+0.83 (+3.00%)
DCF Value
$89.04
Tangible Book / Share
$4.09
Graham Number
$31.63
Cash / Share
$5.42
Clinical Trials (21)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04207840 Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals | Pharmacokinetics, Epinephrine | P4 | Completed | 28 | RCT, Single-blind | — |
| NCT07560150 Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers | Pharmacokinetics, Pharmacodynamics | P2P3 | Completed | 62 | RCT, Double-blind | I004, NovoLog |
| NCT01357642 Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients | Asthma | P3 | Completed | 373 | RCT, Double-blind | Epinephrine inhalation aerosol, Placebo, epinephrine inhalation aerosol |
| NCT00634829 Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction | Asthma, Bronchospasm | P3 | Terminated | 24 | RCT, Double-blind | albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA |
| NCT00634517 4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma | Asthma | P3 | Terminated | 48 | RCT, Double-blind | Armstrong Albuterol Sulfate Inhalation Aerosol, Albuterol Sulfate Inhalation Aerosol |
| NCT01737905 Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma | Asthma | P3 | Completed | 28 | RCT, Double-blind | Epinephrine HFA-MDI (E004), Placebo-HFA |
| NCT01460511 Evaluation of Efficacy and Safety of E004 in Children With Asthma | Asthma | P3 | Completed | 70 | RCT, Double-blind | E004 (Epinephrine Inhalation Aerosol) HFA-MDI, Placebo-HFA |
| NCT05539872 Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers | Pharmacokinetics, Pharmacodynamics | P2P3 | Completed | 69 | RCT, Double-blind | I004, NovoLog |
| NCT01476904 Safety Study in Adolescent and Adult Patients With Asthma | Asthma | P3 | Completed | 208 | RCT, Double-blind | Placebo, Primatene Mist, Epinephrine inhalation |
| NCT00635505 Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients | Asthma | P3 | Terminated | 300 | RCT, Double-blind | albuterol HFA (Armstrong's), albuterol HFA (Proventil HFA), HFA placebo |
| NCT01737892 Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults | Asthma | P1P2 | Terminated | 21 | RCT, Single-blind | Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC |
| NCT01174732 Dose-Ranging Study of A006 DPI, in Adult Asthma Patients | Asthma, Bronchospasm | P2 | Completed | 26 | RCT, Double-blind | albuterol inhalation powder, albuterol inhalation powder, albuterol inhalation powder, albuterol inhalation powder, Placebo, albuterol inhalation aerosol, albuterol inhalation aerosol |
| NCT01689363 Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) | Allergic Skin Reaction | P2 | Completed | 253 | RCT, Double-blind | Hyaluronidase, Histamine, Saline |
| NCT02210806 Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation | Asthma | P2 | Completed | 22 | RCT, Double-blind | A006 DPI, A006 DPI, Proventil® MDI, Proventil® MDI |
| NCT01188577 Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics | Asthma, Bronchospasm | P1P2 | Completed | 23 | RCT, Double-blind | Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol |
| NCT01189396 Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006 | Asthma, Bronchospasm | P2 | Completed | 27 | RCT, Double-blind | A006, Placebo DPI, Proventil-HFA |
| NCT01581177 Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation | Asthma | P2 | Completed | 23 | RCT, Double-blind | Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh |
| NCT01143051 Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers | Asthma | P1P2 | Completed | 24 | RCT, Double-blind | epinephrine inhalation aerosol, epinephrine inhalation aerosol, epinephrine inhalation aerosol |
| NCT01255709 Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS | Asthma | P2 | Completed | 24 | RCT, Double-blind | Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP) |
| NCT02271334 Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers | Asthma | P2 | Completed | 22 | RCT, Double-blind | A006 DPI, A006 DPI, Proventil® MDI, Proventil® MDI |
| NCT01025648 Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients. | Asthma | P1P2 | Terminated | 9 | RCT, Double-blind | E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg |